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Abstract
The Alzheimer’s Disease Prediction Of Longitudinal Evolution (TADPOLE) Challenge compares the performance of algorithms at
predicting future evolution of individuals at risk of Alzheimer’s disease. TADPOLE Challenge participants train their models and
algorithms on historical data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) study or any other datasets to which
they have access. Participants are then required to make monthly forecasts over a period of 5 years from January 2018, of three
key outcomes for ADNI-3 rollover participants: clinical diagnosis, Alzheimer’s Disease Assessment Scale Cognitive Subdomain
(ADAS-Cog13), and total volume of the ventricles. These individual forecasts are later compared with the corresponding future
measurements in ADNI-3 (obtained after the TADPOLE submission deadline). The first submission phase of TADPOLE was open
for prize-eligible submissions between 15 June and 15 November 2017. The submission system remains open via the website:
https://tadpole.grand-challenge.org, although since 15 November 2017 submissions are not eligible for the first round of
prizes. This paper describes the design of the TADPOLE Challenge.
Keywords: Alzheimer’s disease, Disease prediction, Community Challenge, Biomarkers
1. Introduction
Alzheimer’s disease (AD), and dementia in general, is a key
challenge for 21st-century healthcare. The statistics are sober-
ing (Winblad et al., 2016): in 2015, 47 million people world-
wide suffer from dementia, of which AD is the most com-
mon cause; dementia costs $818 billion worldwide, which is
more than 1% of the aggregaste global gross domestic product
(GDP); AD might contribute to as many deaths as does heart
disease or cancer. There are no available treatments that can
cure or even slow the progression of AD – all clinical trials into
putative treatments have failed to prove a disease-modifying ef-
fect. One key reason for these failures is the difficulty in iden-
tifying a group of patients at early stages of the disease, where
treatments are most likely to be effective.
While early and accurate diagnosis of dementia can be chal-
lenging, this can be aided by quantitative biomarker measure-
ments taken from magnetic resonance imaging (MRI), positron
emission tomography (PET), and cerebro-spinal fluid (CSF)
samples extracted from lumbar puncture. It has been hypoth-
esized for AD (Jack Jr et al., 2010, 2013; Aisen et al., 2010;
Frisoni et al., 2010) that all these biomarkers become abnor-
mal at different intervals before symptom onset, suggesting that
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together they can be used for accurate prediction of onset and
overall disease progression in individuals. In particular, some
of the early biomarkers become abnormal decades before symp-
tom onset, and can thus facilitate early diagnosis.
Several approaches for predicting AD-related target vari-
ables (e.g. clinical diagnosis, cognitive/imaging biomarkers)
have been proposed which leverage multimodal biomarker data
available in AD. Traditional longitudinal approaches based on
statistical regression model the relationship of the target vari-
ables with other known variables. Examples include regres-
sion of the target variables against clinical diagnosis (Scahill
et al., 2002), cognitive test scores (Yang et al., 2011; Sabuncu
et al., 2011), rate of cognitive decline (Doody et al., 2010), and
retrospectively staging subjects by time to conversion between
diagnoses (Guerrero et al., 2016). Another approach involves
supervised machine learning techniques such as support vector
machines, random forests, and artificial neural networks, which
use pattern recognition to learn the relationship between the val-
ues of a set of predictors (biomarkers) and their labels (diag-
noses). These approaches have been used to discriminate AD
patients from cognitively normal individuals (Klo¨ppel et al.,
2008; Zhang et al., 2011), and for discriminating at-risk individ-
uals who convert to AD in a certain time frame from those who
do not (Young et al., 2013; Mattila et al., 2011). The emerging
approach of disease progression modelling aims to reconstruct
biomarker trajectories or other disease signatures across the
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disease progression timeline, without relying on clinical diag-
noses or estimates of time to symptom onset. Examples include
models built on a set of scalar biomarkers to produce discrete
(Fonteijn et al., 2012; Young et al., 2014) or continuous (Jedy-
nak et al., 2012; Donohue et al., 2014; Villemagne et al., 2013)
biomarker trajectories; richer but less comprehensive models
that leverage structure in data such as MR images (Durrleman
et al., 2013; Lorenzi et al., 2015; Bilgel et al., 2016); and models
of disease mechanisms (Seeley et al., 2009; Zhou et al., 2012;
Raj et al., 2012; Iturria-Medina et al., 2016).
These models have shown promise for predicting AD
biomarker progression when using existing test data, but few
have been tested on truly unseen future data. Moreover, dif-
ferent investigators test these models on different datasets (in-
cluding subsets of a single dataset) and use different processing
pipelines. Community challenges have proved effective, in the
medical image analysis field and beyond, for providing unbi-
ased comparative evaluations of algorithms and tools designed
for a particular task. Previous challenges that focussed on pre-
diction of AD progression include the CADDementia challenge
(Bron et al., 2015), which aimed to predict clinical diagnosis
from MRI scans. A similar challenge, the ”International chal-
lenge for automated prediction of MCI from MRI data” (Sarica
et al., 2018) asked participants to predict diagnosis and conver-
sion status from extracted MRI features of subjects from the
ADNI study (Weiner et al., 2017). Yet another challenge, The
Alzheimer’s Disease Big Data DREAM Challenge (Allen et al.,
2016), asked participants to predict cognitive decline from ge-
netic and MRI data.
The Alzheimer’s Disease Prediction Of Longitudinal Evo-
lution (TADPOLE) Challenge aims to identify the data, fea-
tures and approaches that are the most predictive of AD pro-
gression. In contrast to previous challenges, our motivation is
to improve future clinical trials through identification of pa-
tients most likely to benefit from an effective treatment, i.e.,
those at early stages of disease who are likely to progress over
the short-to-medium term (1-5 years). Identifying such sub-
jects reliably helps cohort selection by focussing on groups that
highlight positive treatment effects. The challenge thus focuses
on forecasting three key features: clinical status, cognitive de-
cline, and neurodegeneration (brain atrophy), over a five-year
timescale. It uses rollover subjects from the ADNI study for
whom a history of measurements is available, and who are ex-
pected to continue in the study, providing future measurements
for testing. Since the test data does not exist at the time of
forecast submissions, the challenge provides a completely un-
biased basis for performance comparison. TADPOLE goes be-
yond previous challenges by drawing on a vast set of multi-
modal measurements from ADNI which support prediction of
AD progression.
2. Competition Design
The aim of TADPOLE is to predict future outcome measure-
ments of subjects at-risk of AD, enrolled in the ADNI study.
A history of informative measurements from ADNI (imaging,
psychology, demographics, genetics, etc.) from each individ-
ual is available to inform forecasts. TADPOLE participants are
required to predict future measurements from these individuals
and submit their predictions before a given submission dead-
line. Evaluation of these forecasts occurs post-deadline, after
the measurements have been acquired. A diagram of the TAD-
POLE flow is shown in Fig 1.
3. Forecasts
Since we do not know the exact time of future data acqui-
sitions for any given individual, TADPOLE challenge partic-
ipants are required to make, for every individual, month-by-
month forecasts of three key biomarkers: (1) clinical diagno-
sis which can be either cognitively normal (CN), mild cogni-
tive impairment (MCI) or probable Alzheimer’s disease (AD);
(2) ADAS-Cog13 (ADAS13) score; and (3) ventricle volume
(divided by intra-cranial volume). Evaluation is performed us-
ing forecasts at the months that correspond to data acquisition.
TADPOLE forecasts are required to be probabilistic and some
evaluation metrics will account for forecast probabilities pro-
vided by participants. Methods or algorithms that do not pro-
duce probabilistic estimates can still be used, by setting binary
probabilities (zero or one) and default confidence intervals.
Participants are required to submit forecasts in a standardised
format (see Table 1). For clinical status, relative likelihoods of
each option (CN, MCI, and AD) for each individual should be
provided. These are normalised at evaluation time; negative
likelihoods are set to zero. For ADAS13 and ventricle volume,
participants need to provide a best-guess value as well as a 50%
confidence interval for each individual. This 50% confidence
interval (as opposed to the more standard 95%) was chosen to
provide a more symmetric and less noisy evaluation of over-
and under-estimation of the confidence interval, because similar
sample sizes of data fall inside and outside the interval.
4. Data
We provide participants with a standard ADNI-derived
dataset (available via the Laboratory Of NeuroImaging: LONI)
which they can use to train their algorithms, removing the need
to pre-process the ADNI data themselves or merge different
spreadsheets. However, participants are allowed to use a cus-
tom training set, by adding any other ADNI data or data from
other studies. The software code used to generate the standard
dataset is openly available in a Github repository1 and on the
ADNI website, packaged with the standard dataset in the LONI
ADNI database.
4.1. ADNI data
Data used in the preparation of this article were obtained
from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
database (adni.loni.usc.edu). The ADNI was launched in
1https://github.com/noxtoby/TADPOLE
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Figure 1: TADPOLE Challenge design. Participants are required to train a predictive model on a training dataset (D1 and/or others)
and make forecasts for different datasets (D2, D3) by the submission deadline. Evaluation will be performed on a test dataset (D4)
that is acquired after the submission deadline.
RID ForecastMonth
Forecast
Date
CN
relative
probability
MCI
relative
probability
AD
relative
probability
ADAS
ADAS
50% CI
lower
ADAS
50% CI
upper
Ventricles
Ventricles
50% CI
lower
Ventricles
50% CI
upper
A 1 2018-01 0 1 0 30 25 35 0.024 0.021 0.029
B 1 2018-01 3 2 0 25 21 26 0.023 0.021 0.025
C 1 2018-01 0.24 0.38 0.38 40 25 50 0.025 0.023 0.028
Table 1: The format of the forecasts for three example subjects.
2003 by the National Institute on Aging (NIA), the National
Institute of Biomedical Imaging and Bioengineering (NIBIB),
the Food and Drug Administration (FDA), private pharmaceu-
tical companies and non-profit organizations, as a $60 million,
5-year public-private partnership. The initial goal of ADNI was
to recruit 800 subjects but ADNI has been followed by ADNI-
GO and ADNI-2. To date these three protocols have recruited
over 1500 adults, ages 55 to 90, to participate in the research,
consisting of cognitively normal older individuals, people with
early or late MCI, and people with early AD. The general ADNI
inclusion criteria has been described in Petersen et al. (2010).
The data we used from ADNI consists of: (1) CSF markers
of amyloid-beta and tau deposition; (2) various imaging modal-
ities such as magnetic resonance imaging (MRI), positron emis-
sion tomography (PET) using several tracers: Fluorodeoxyglu-
cose (FDG, hypometabolism), AV45 (amyloid), AV1451 (tau)
as well as diffusion tensor imaging (DTI); (3) cognitive assess-
ments acquired in the presence of a clinical expert; (4) genetic
information such as alipoprotein E4 (APOE4) status extracted
from DNA samples; and (5) general demographic information.
Extracted features from this data were merged together into a
final spreadsheet and made available on the LONI ADNI web-
site.
4.2. Image pre-processing
The imaging data has been pre-processed with standard
ADNI pipelines. For MRI scans, this included correction for
gradient non-linearity, B1 non-uniformity correction and peak
sharpening2. Meaningful regional features such as volume and
cortical thickness were extracted using the Freesurfer cross-
sectional and longitudinal pipelines (Reuter et al., 2012). Each
PET image (FDG, AV45, AV1451), which consists of a series of
dynamic frames, had its frames co-registered, averaged across
the dynamic range, standardised with respect to the orienta-
tion and voxel size, and smoothed to produce a uniform res-
olution of 8mm full-width/half-max (FWHM)3. Standardised
uptake value ratio (SUVR) measures for relevant regions-of-
interest were extracted (see Jagust et al. (2010)) after registering
the PET images to corresponding MR images using the SPM5
software (Ashburner, 2009). DTI scans were corrected for
head motion and eddy-current distortion, skull-stripped, EPI-
corrected, and finally aligned to the T1 scans using the pipeline
from Nir et al. (2013). Diffusion tensor summary measures
were estimated based on the Eve white-matter atlas by Oishi
et al. (2009).
5. TADPOLE Datasets
The TADPOLE Challenge involves three kinds of data sets:
(a) a training data set, which is a collection of measurements
with associated outcomes that can be used to fit models or train
algorithms; (b) a prediction data set, which contains only base-
line measurements (possibly longitudinal), without associated
2see MRI analysis on ADNI website: http://adni.loni.usc.edu/
methods/mri-analysis/mri-pre-processing
3see PET analysis on ADNI website: http://adni.loni.usc.edu/
methods/pet-analysis/pre-processing
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outcomes — this is the data that algorithms, models, or experts
use as input to make their forecasts of later patient status and
outcome; and (c) a test data set, which contains the patient
outcomes against which we will evaluate forecasts — in TAD-
POLE, this data did not exist at the time of submitting forecasts.
In order to evaluate the effect of different methodological
choices, we prepared three standard data sets for training and
prediction:
• D1: The TADPOLE standard training set draws on longi-
tudinal data from the entire ADNI history. The data set
contains a set of measurements for every individual that
has provided data to ADNI in at least two separate visits
(different dates) across three phases of the study: ADNI1,
ADNI GO, and ADNI2.
• D2: The TADPOLE longitudinal prediction set contains
as much available data as we could gather from the ADNI
rollover individuals for whom challenge participants are
asked to provide forecasts. D2 includes all available time-
points for these individuals.
• D3: The TADPOLE cross-sectional prediction set con-
tains a single (most recent) time point and a limited set of
variables from each rollover individual in D2. Although
we expect worse forecasts from this data set than D2, D3
represents the information typically available when select-
ing a cohort for a clinical trial.
The forecasts will be evaluated on future data (D4 – test set)
from ADNI3 rollovers, acquired after the challenge submission
deadline. In addition to the three standard datasets (D1, D2 and
D3), challenge participants are allowed to use any other data
sets that might serve as useful additional training data.
Fig. 2 shows a diagram highlighting the nested structure of
datasets D1–D3. Table 2 shows the proportion of biomarker
data available in each dataset. There are a considerable number
of entries with missing data, especially for some biomarkers
such as tau imaging (AV1451). We also estimated the expected
number of subjects and available data for D4, using information
from the ADNI3 procedures and using rollovers from previous
ADNI studies (Table 2, right-most column) – See Appendix A
for more information on D4 estimates. Based on our estimates,
we believe the size of D4 (around 330 subjects, 1 visit/subject)
should be enough for a reliable evaluation of TADPOLE sub-
missions.
6. Submissions
There are two kinds of submissions that challenge partici-
pants can make. A simple entry requires a minimal forecast
and a description of methods; it makes participants eligible for
the prizes but not co-authorship on the scientific paper docu-
menting the results. A simple entry can use any training data or
prediction sets and forecast at least one of the target outcome
variables (clinical status, ADAS13 score, or ventricle volume).
A full entry entitles participants for consideration as a co-author
Subject statistics D1 D2 D3 D4
Nr. of subjects 1667 896 896 330
Visits per subject 7.6±3.8 8.5±4.2 1.0±0.0 1.0±0.0
CN 31 38 45 39
Diagnosis* (%) MCI 56 57 39 49
AD 13 5 16 12
Data availability**
Cognitive tests (%) 70 68 84 62
MRI (%) 62 56 75 69
FDG-PET (%) 16 20 0 20
AV45-PET (%) 16 22 0 19
AV1451-PET (%) 0.7 1.1 0 19
DTI (%) 6 8 0 15
CSF (%) 18 19 0 14
Table 2: Biomarker summary of TADPOLE datasets D1, D2
and D3. There is considerable amount of missing data in some
biomarkers such as AV1451. Numbers for D4 are estimated
based on ADNI3 procedures (see ADNI3 procedures manual)
and rollovers from previous ADNI studies. (*) Diagnosis at
baseline visit. (**) Percentage of all visits (across all subjects)
that have measurements for desired biomarker.
on the publication documenting the results. Such a full entry re-
quires a complete forecast for all three outcome variables on all
subjects from the D2 prediction set, along with a description of
the methods. Each individual participant is limited to a maxi-
mum of three submissions. This restriction has been introduced
to avoid the risk of participants tuning their method on the test
set by submitting multiple predictions for a range of algorithm
settings. Although not required for a full entry, participants are
strongly encouraged to submit predictions also for D3.
Prizes are awarded to the best entries regardless of the choice
of training sets (D1/custom) and prediction sets (D2/D3). How-
ever, the additional submissions support the key scientific aims
of the challenge by allowing us to separate the influence of
the choice of training data, post-processing pipelines, and mod-
elling techniques or prediction algorithms. The target variables
used for evaluation, in particular ventricle volume, will use the
same post-processing pipeline as the standard data sets D1-D3.
Beyond the standard training dataset (D1), participants can
include additional forecasts from ”custom” (i.e. constructed by
the participant) training data or custom post-processing of the
raw data from subjects in the standard training set. The same
applies to the prediction sets D2 and D3, which can be cus-
tomised by the participants if desired, e.g. a prediction set with
different features from the same individuals as in D2 and D3.
Table 3 shows the twelve possible combinations of subject sets,
processing and prediction sets, from which a full-entry submis-
sion must contain at least one of the first four (ID 1–4).
7. Forecast Evaluation
7.1. Clinical Status Prediction
For evaluation of clinical status predictions, we will use sim-
ilar metrics to those that proved effective in the CADDementia
4
Figure 2: Venn diagram of the ADNI datasets for training (D1), longitudinal prediction (D2), cross-sectional prediction (D3) and
the test set (D4). D3 is a subset of D2, which in turn is a subset of D1. Other non-ADNI data can also be used for training.
ID Training set Prediction set
Subject set Post-processing
1 D1 standard D2
2 D1 custom D2
3 custom standard D2
4 custom custom D2
5 D1 standard D3
6 D1 custom D3
7 custom standard D3
8 custom custom D3
9 D1 standard custom
10 D1 custom custom
11 custom standard custom
12 custom custom custom
Table 3: Types of submissions that can be made by partici-
pants, for different types of training sets, prediction sets and
post-processing pipelines.
challenge (Bron et al., 2015): (i) the multiclass area under the
receiver operating curve (mAUC); and (ii) the overall balanced
classification accuracy (BCA). The mAUC is independent of
the group sizes and gives an overall measure of classification
ability that accounts for relative likelihoods assigned to each
class. The simpler BCA is also independent of group sizes, but
does not exploit the probabilistic nature of the forecasts.
7.1.1. Multiclass Area Under the Receiver Operating Charac-
teristic (ROC) Curve
The multiclass Area Under the ROC Curve (mAUC) is a sim-
ple generalisation of the area under the ROC curve applicable
to problems with more than two classes (Hand and Till, 2001).
The AUC Aˆ(ci|c j) for classification of a class ci against another
class c j, is:
Aˆ(ci|c j) = S i − ni(ni + 1)/2nin j (1)
where ni and n j are the number of points belonging to classes
i and j, respectively; while S i is the sum of the ranks of
the class i test points after ranking all the class i and j data
points in increasing likelihood of belonging to class i. We fur-
ther define the average AUC for classes i and j as Aˆ(ci, c j) =
0.5(Aˆ(ci|c j) + Aˆ(c j|ci)). The overall mAUC is then obtained by
averaging Aˆ(ci, c j) over all pairs of classes:
mAUC =
2
L(L − 1)
L∑
i=2
i∑
j=1
Aˆ(ci, c j) (2)
where L is the number of classes. The class probabilities that
go into the calculation of S i in the first equation are pCN , pMCI
and pAD, which are derived from the likelihoods of each ADNI
subject being assigned to each diagnostic class, by normalising
to have unity sum.
7.1.2. Balanced Classification Accuracy
The Balanced Classification Accuracy (see Brodersen et al.
(2010)) is an extension of the classification accuracy measure
that accounts for the imbalance in the numbers of datapoints
belonging to each class. However, the measure is not proba-
bilistic, so in TADPOLE the data points need to be assigned
a hard classification to the class (CN, MCI, or AD) with the
highest likelihood. The balanced accuracy for class i is then:
BCAi =
1
2
[ T P
T P + FN
+
T N
T N + FP
]
(3)
where TP, FP, TN, FN represent the number of true positives,
false positives, true negatives and false negatives for classifica-
tion as class i. In this case, true positives are data points with
true label i and correctly classified as such, while the false neg-
atives are the data points with true label i and incorrectly classi-
fied to a different class j , i. True negatives and false positives
are defined similarly. The overall BCA is given by the mean of
all the balanced accuracies for every class.
7.2. Continuous Feature Predictions
For ADAS13 and ventricle volume, we will use three met-
rics: mean absolute error (MAE), weighted error score (WES)
and coverage probability accuracy (CPA). The MAE focuses
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purely on accuracy of the best-guess prediction ignoring the
confidence interval, whereas the WES incorporates confidence
estimates into the error score. The CPA provides an assessment
of the accuracy of the confidence estimates, irrespective of the
best-guess prediction accuracy.
7.2.1. Mean Absolute Error
The mean absolute error (MAE) is:
MAE =
1
N
N∑
i=1
∣∣∣M˜i − Mi∣∣∣ (4)
where N is the number of data points (forecasts) evaluated, Mi
is the actual biomarker value in individual i in future data, and
M˜i is the participant’s best prediction for Mi.
7.2.2. Weighted Error Score
The weighted error score is defined as:
WES =
∑N
i=1 C˜i
∣∣∣M˜i − Mi∣∣∣∑N
i=1 C˜i
(5)
where the weightings C˜i are the participant’s relative confi-
dences in their M˜i. We estimate C˜i as the inverse of the width
of the 50% confidence interval of their biomarker estimate:
C˜i = (C+ −C−)−1 (6)
where [C−,C+] is the confidence interval provided by the par-
ticipant.
7.2.3. Coverage Probability Accuracy
The coverage probability accuracy is:
CPA = |ACP − NCP| (7)
where NCP is the nominal coverage probability, the target for
the confidence intervals, and ACP is the actual coverage proba-
bility, defined as the proportion of measurements that fall within
the corresponding confidence interval. In TADPOLE, we set
NCP to be 0.5, which means that ideally only 50% of the mea-
surements would fall inside the confidence interval. The CPA
can take values between 0 and 1, and lower scores are better.
8. Prizes
We are extremely grateful to Azheimer’s Research UK, The
Alzheimer’s Society, and The Alzheimer’s Association for
sponsoring a prize fund of £30,000. At the time of first sub-
mission, we proposed six separate prizes, as outlined in Table
4, but reserve the right to reallocate the prize money depending
on the numbers of participants eligible for each prize. The first
four are general categories (open to all challenge participants)
and constitute one prize for the best forecast of each feature as
well as one for overall best performance. The last two prizes
are for two different student categories.
Prize
amount Outcome measure
Performance
Metric Eligibility
£5,000 Clinical status mAUC all
£5,000 ADAS13 MAE all
£5,000 Ventricle volume MAE all
£5,000 Overall best
Lowest sum
of ranks* all
£5,000 Clinical status mAUC
University
teams
£5,000 Clinical status mAUC
High-school
teams
Table 4: Prize allocation scheme using funds from Azheimer’s
Research UK, The Alzheimer’s Society and The Alzheimer’s
Association. There are 6 prizes awarded to different outcome
measures, the last two of which are eligible only for university
and high-school teams. (*) The overall best team will be the
team that obtains the lowest sum of ranks in the clinical status,
ADAS13 and ventricle volume categories.
9. Discussion
We have outlined the design of the TADPOLE Challenge,
which aims to identify algorithms and features that can best
predict the evolution of Alzheimer’s disease. Challenge partic-
ipants use historical data from ADNI in order to predict three
key outcomes: clinical diagnosis, ADAS-Cog13 and ventricle
volume. Determining which features and algorithms best pre-
dict AD evolution can aid refinement of cohorts and endpoint
assessment for clinical trials, and can provide accurate prognos-
tic information in clinical settings.
The TADPOLE Challenge was designed to be transparent
and accessible. To this end, all of our scripts are available in
an open repository4. We also created a public forum5 where we
answer participant questions. Finally, in order to enable par-
ticipants to share algorithm performance results throughout the
competition, we created a leaderboard system6 that evaluates
submissions on an existing test dataset and publishes the results
live on our website.
Going forward, we hope that by November 2018 sufficient
data will be available from ADNI3 rollovers for a first mean-
ingful evaluation of the forecasts. We plan to publish the results
on the website in January 2019, and then submit a publication
of the results soon after. However, we reserve the right to delay
evaluation until sufficient data is available. At that time, we will
also evaluate the impact and interest of the first phase of TAD-
POLE within the community, to guide decisions on whether to
organise further submission and evaluation phases.
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Appendix A. Expected number of subjects and available
data for D4
We estimated the number of subjects and available data in
D4 (Table 2, last column) using information from the ADNI
procedures manual and previous ADNI rollovers. For estimat-
ing the total number of subjects (first row) expected in D4, we
computed the dropout rate (0.36) based on ADNI1 rollovers to
ADNI2, then multiplied it by the total number of subjects in D2
(896). For estimating the proportions of each diagnostic cat-
egory (third row), we used the proportion of diagnostic rates
in D2 and multiplied them with conversion rates within 1 year
from ADNI1/GO/2 (see website FAQ). For estimating the aver-
age number of visits per subject (mean ± std.) in D4 (second
row), we used the proportions for each diagnostic group and
considered one visit per subject (ADNI procedures). We set the
standard deviation to be zero, although in practice this won’t be
the case.
For estimating the available biomarker data (lower half of
table), we used a 1-year time-frame from start of ADNI2
(July 2012 – July 2013) and computed the proportion of avail-
able data in that time frame. For AV1451, we used the
same estimate as for AV45, due to the fact that the scan
was introduced later on in ADNI2, and we expect more
subjects to undergo AV1451 scans in ADNI3. A Python
script that computes all the data from Table 2 is given in
the TADPOLE repository: https://github.com/noxtoby/
TADPOLE/blob/master/statistics/tadpoleStats.py.
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